Targeted agents have continued to reshape the treatment landscape of acute leukemia (AL), improving efficacy and safety. A team led by Dr. Kaiqi Liu at the Leukemia Diagnosis and Treatment Center of the Institute of Hematology, Chinese Academy of Medical Sciences (CAMS), in collaboration with multiple domestic centers, has reported two studies — one in Blood Cancer Journal and one in Haematologica — that push beyond the current National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology and provide important evidence for new AL treatment strategies.
FLT3-ITD-Positive AML: Venetoclax Plus Intensive Chemotherapy
FLT3 internal tandem duplication (FLT3-ITD) is among the most common mutations in acute myeloid leukemia (AML). Patients carrying this mutation have historically achieved complete remission (CR) rates of only 40-60% with conventional chemotherapy and have faced elevated relapse risk. Current NCCN guidelines recommend a FLT3 inhibitor combined with chemotherapy and subsequent allogeneic hematopoietic stem cell transplantation (allo-HSCT) to improve long-term outcomes.
Liu’s team reported, for the first time internationally, the efficacy of venetoclax (VEN) combined with intensive chemotherapy in FLT3-ITD-positive AML, with a CR rate exceeding 90% — notably superior to the FLT3-inhibitor-plus-chemotherapy benchmark in the NCCN guidelines. A striking observation: only 19.0% of patients in this cohort proceeded to allo-HSCT, far below the 59-72% transplantation rates reported in prior pivotal studies, yet survival outcomes appeared comparable. The findings suggest that VEN plus intensive chemotherapy can induce deep remission in AML, calling into question the absolute necessity of allo-HSCT in this patient subset. This work was recently published in Blood Cancer Journal, with Dr. Kaiqi Liu (Associate Chief Physician) and Dr. Yingchang Mi (Chief Physician) of the Institute of Hematology, CAMS, and Dr. Zeping Zhou (Chief Physician) of the Second Affiliated Hospital of Kunming Medical University as co-corresponding authors.
https://www.nature.com/articles/s41408-026-01558-z
R/R T-ALL: Dara-VDVD Regimen
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive and highly heterogeneous hematologic malignancy, and patients with relapsed or refractory (R/R) disease have very poor outcomes with conventional chemotherapy. Newer agents — the BCL-2 inhibitor venetoclax, the CD38 monoclonal antibody daratumumab (Dara), and chimeric antigen receptor T-cell (CAR-T) therapies — have brought new hope, but the optimal regimen remains undefined.
Liu’s earlier work had shown that a three-day multi-frequency decitabine plus venetoclax (DEC3-VEN) regimen yielded strong efficacy in elderly AML (composite CR rate 86.7%). Building on this, the team combined DEC3-VEN with daratumumab, vincristine (VCR), and dexamethasone (DXM) to form the Dara-VDVD regimen and tested it as reinduction therapy in 10 R/R T-ALL patients.
The Dara-VDVD regimen showed several advantages:
1. Strong efficacy. After one cycle, the CR rate was 90%, markedly higher than historical controls with VEN plus azacitidine (VEN+AZA; CR ~68%) or daratumumab plus chemotherapy (CR ~40-60%).
2. Favorable safety. Despite the multi-agent combination, there were no treatment-related deaths, and elderly patients (two patients aged ≥70 years) also tolerated the regimen.
3. Transplant bridge. Allo-HSCT remains the only curative option for this disease. Dara-VDVD effectively reduced tumor burden, creating conditions favorable for subsequent transplantation.
4. Broad applicability. Efficacy was observed in both early precursor T-ALL (ETP-ALL) and non-ETP-ALL subtypes.
The work was recently published in Haematologica, with Dr. Kaiqi Liu and Dr. Yingchang Mi of the Institute of Hematology, CAMS, and Dr. Xiaohui Suo (Chief Physician) of Handan Central Hospital as co-corresponding authors.
https://haematologica.org/article/view/14325
References
[1] Yuyu Liu, Guanchen Bai, Xingli Zhao, et al. Venetoclax combined with intensive chemotherapy as induction chemotherapy in newly diagnosed AML with FLT3-ITD-mutation. Blood Cancer J. 2026 Jun 23;16(1):101.
[2] Congcong Zhang, Fang Zheng, Liyun Zhao, et al. Daratumumab combining with venetoclax, three-day multi-frequency decitabine, vincristine, dexamethasone (VDVD) as the salvage treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. Haematologica. 2026 Jul 30.